SG11201809882XA - Pharmaceutical combinations for treating cancer - Google Patents

Pharmaceutical combinations for treating cancer

Info

Publication number
SG11201809882XA
SG11201809882XA SG11201809882XA SG11201809882XA SG11201809882XA SG 11201809882X A SG11201809882X A SG 11201809882XA SG 11201809882X A SG11201809882X A SG 11201809882XA SG 11201809882X A SG11201809882X A SG 11201809882XA SG 11201809882X A SG11201809882X A SG 11201809882XA
Authority
SG
Singapore
Prior art keywords
international
pct
pharmaceutical combinations
stettenweg
schollhorn
Prior art date
Application number
SG11201809882XA
Inventor
Alexander Bausch
Original Assignee
Support Venture Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to EP16173443 priority Critical
Application filed by Support Venture Gmbh filed Critical Support Venture Gmbh
Priority to PCT/EP2017/063714 priority patent/WO2017211830A1/en
Publication of SG11201809882XA publication Critical patent/SG11201809882XA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/427Thiazoles not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Abstract

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property 1111111011110111011111111010111110011111111111111111111111111111111111111111111111 Organization 0 International Bureau (10) International Publication Number (43) International Publication Date .....0\"\"\" WO 2017/211830 Al 14 December 2017 (14.12.2017) WIP0 I PCT (51) International Patent Classification: A61K 45/06 (2006.01) A61K 31/519 (2006.01) A61K 31/4439 (2006.01) A61P 35/00 (2006.01) (21) International Application Number: PCT/EP2017/063714 (22) International Filing Date: 06 June 2017 (06.06.2017) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 16173443.9 08 June 2016 (08.06.2016) EP (71) Applicant: SUPPORT-VENTURE GMBH [CH/CH]; Stettenweg 16, 4125 Riehen (CH). (72) Inventor: BAUSCH, Alexander; Stettenweg 16, 4125 Riehen (CH). (74) Agent: SCHOLLHORN, Andreas; Latscha Schollhorn Partner AG, Austrasse 24, 4051 Basel (CH). Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. = (81) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). = (84) under Rule 4.17: Declarations — as to applicant's entitlement to apply for and be granted a patent (Rule 4.1700) 1- 2 0 , 1 Published: with international search report (Art. 21(3)) 0 M GC Il Il ei IN 1-1 (54) Title: PHARMACEUTICAL COMBINATIONS FOR TREATING CANCER 0 ei (57) : The present invention relates to pharmaceutical combinations comprising a PPAR agonist 0 a method for the prevention, delay of progression or treatment of cancer. and a P38 ihibitor for use in
SG11201809882XA 2016-06-08 2017-06-06 Pharmaceutical combinations for treating cancer SG11201809882XA (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP16173443 2016-06-08
PCT/EP2017/063714 WO2017211830A1 (en) 2016-06-08 2017-06-06 Pharmaceutical combinations for treating cancer

Publications (1)

Publication Number Publication Date
SG11201809882XA true SG11201809882XA (en) 2018-12-28

Family

ID=56132777

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201809882XA SG11201809882XA (en) 2016-06-08 2017-06-06 Pharmaceutical combinations for treating cancer

Country Status (22)

Country Link
US (1) US20190160072A1 (en)
EP (1) EP3468604B1 (en)
JP (1) JP2019517562A (en)
KR (1) KR20190017756A (en)
CN (1) CN109414506A (en)
AU (1) AU2017277478A1 (en)
BR (1) BR112018075135A2 (en)
CA (1) CA3023392A1 (en)
CL (1) CL2018003509A1 (en)
CO (1) CO2018013020A2 (en)
DK (1) DK3468604T3 (en)
EA (1) EA201892287A1 (en)
HU (1) HUE053648T2 (en)
IL (1) IL263407D0 (en)
MX (1) MX2018014938A (en)
PE (1) PE20190376A1 (en)
PH (1) PH12018550186A1 (en)
PL (1) PL3468604T3 (en)
PT (1) PT3468604T (en)
SG (1) SG11201809882XA (en)
UA (1) UA123914C2 (en)
WO (1) WO2017211830A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112019003006A2 (en) * 2016-08-17 2019-05-14 Support-Venture Gmbh use of a pharmaceutical combination and kit to prevent or treat hearing loss
JP2019524888A (en) * 2016-08-18 2019-09-05 インテクリン セラピューティクス インコーポレイテッド PPARγ agonists for the treatment of blood cancer
US10342786B2 (en) * 2017-10-05 2019-07-09 Fulcrum Therapeutics, Inc. P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR240698A1 (en) 1985-01-19 1990-09-28 Takeda Chemical Industries Ltd Process for the preparation of 5-(4-(2-(5-ethyl-2-pyridil)-ethoxy)benzyl)-2,4-thiazolodinedione and their salts
ES2249574T3 (en) * 2001-02-12 2006-04-01 F. Hoffmann-La Roche Ag PIRIDO-PIRIMIDINAS 6-REPLACED.
US20030212138A1 (en) * 2002-01-14 2003-11-13 Pharmacia Corporation Combinations of peroxisome proliferator-activated receptor-alpha agonists and cyclooxygenase-2 selective inhibitors and therapeutic uses therefor
CN1771034A (en) * 2002-01-14 2006-05-10 法马西亚公司 Combinations of peroxisome proliferators-activated receptor-alpha agonists and cyclooxygenase-2 selective inhibitors and therapeutic uses therefor
WO2005047284A1 (en) 2003-11-13 2005-05-26 F. Hoffmann-La Roche Ag Hydroxyalkyl substituted pyrido-7-pyrimidin-7-ones
WO2006127678A2 (en) * 2005-05-23 2006-11-30 Smithkline Beecham Corporation Inhibition of p38 mark for treatment of obesity
AU2007257959A1 (en) * 2006-06-09 2007-12-21 Kemia, Inc. Therapy using cytokine inhibitors
JP2010529973A (en) 2007-06-15 2010-09-02 エフ.ホフマン−ラ ロシュ アーゲー Novel process for producing 3-amino-pentane-1,5-diol
WO2010071583A1 (en) * 2008-12-18 2010-06-24 Astrazeneca Ab Pharmaceutical product comprising a p38 kinase inhibitor and a second active ingredient
CA2789847A1 (en) * 2010-02-15 2011-08-18 Synovo Gmbh Kinase modulators for the treatment of cancer

Also Published As

Publication number Publication date
PT3468604T (en) 2021-04-06
PE20190376A1 (en) 2019-03-08
PH12018550186A1 (en) 2019-03-18
HUE053648T2 (en) 2021-07-28
CO2018013020A2 (en) 2018-12-28
KR20190017756A (en) 2019-02-20
DK3468604T3 (en) 2021-04-19
EP3468604B1 (en) 2021-01-20
EP3468604A1 (en) 2019-04-17
BR112018075135A2 (en) 2019-03-26
PL3468604T3 (en) 2021-07-12
MX2018014938A (en) 2019-05-16
AU2017277478A1 (en) 2018-11-22
EA201892287A1 (en) 2019-06-28
IL263407D0 (en) 2018-12-31
CL2018003509A1 (en) 2019-03-15
CA3023392A1 (en) 2017-12-14
US20190160072A1 (en) 2019-05-30
WO2017211830A1 (en) 2017-12-14
JP2019517562A (en) 2019-06-24
UA123914C2 (en) 2021-06-23
CN109414506A (en) 2019-03-01

Similar Documents

Publication Publication Date Title
SG11201908813QA (en) Anti-sirp alpha antibodies
SG11201805044WA (en) Compounds useful as kinase inhibitors
SG11201908567UA (en) Modified cyclic dinucleotide compounds
SG11201900480YA (en) Anti-tim-3 antibodies
SG11201808566WA (en) Polymorphic form of n-{6-(2-hydroxypropan-2-yl)-2-[2-(methylsulphonyl)ethyl]-2h-indazol-5-yl}-6-(trifluoromethyl)pyridine-2-carboxamide
SG11201903061YA (en) Combination treatments comprising administration of imidazopyrazinones
SG11201809882XA (en) Pharmaceutical combinations for treating cancer
SG11201808222RA (en) Methods of treatment of cholestatic diseases
SG11201809172WA (en) Crystalline forms of n-[2-(3-hydroxy-3-methylbutyl)-6-(2-hydroxypropan-2-yl)-2h-indazol-5-yl]-6-(trifluoromethyl)pyridine-2-carboxamide
SG11201811432WA (en) Rna for cancer therapy
SG11201811431VA (en) Multispecific antibodies against cd40 and cd137
SG11201909680UA (en) Phenyl-2-hydroxy-acetylamino-2-methyl-phenyl compounds
SG11201807827VA (en) Process for the preparation of pegylated drug-linkers and intermediates thereof
SG11201805149XA (en) Compositions comprising 15-hepe and methods of using the same
SG11201804587QA (en) Isoindole compounds
SG11201907308UA (en) Pharmaceutical combination comprising ponesimod
SG11201907804QA (en) Pharmaceutical composition comprising selexipag
SG11201901477PA (en) Compound for use in the treatment of neurogenic orthostatic hypotension
SG11201901048VA (en) Pharmaceutical compositions and uses directed to lysosomal storage disorders
SG11201806157WA (en) Method and pharmaceutical composition for treatment of neurodegeneration
SG11201906991PA (en) A method of inhibiting isomerization of a reducing saccharide upon thermal treatment
SG11201907034PA (en) Methods of treating influenza
SG11201903911UA (en) Combinations of fgfr4 inhibitors and bile acid sequestrants
SG11201808713YA (en) Ophthalmic compositions comprising levodopa, an antioxidant and an aqueous carrier
SG11201903057XA (en) Treatment of cholangiocarcinoma with tpcs-2a induced photochemical internalisation of gemcitabine